1. Kashtan CE, Ding J, Garosi G, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV a345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int. 2018;93(5):1045-1051. 2. Savige J, Colville D, Rheault M, et al. Alport syndrome in women and girls. Clin J Am Soc Nephrol. 2016;11(9):1713-1720. 3. Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306. 4. Wright JT Jr, Bakris G, Greene T, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421-2431. 5. Torres VE, Chapman AB, Devuyst O, et al; REPRISE Trial Investigators. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930-1942. 6. Chertow GM, Appel GB, Anderoli S, et al. Study design and baseline characteristics of the CARDINAL trial: a phase 3 study of bardoxolone methyl in patients with Alport syndrome. Am J Nephrol. 2021;52(3):180-189. 7. Nestor JG, Groopman EE, Gharavi AG. Towards precision nephrology: the opportunities and challenges of genomic medicine. J Nephrol. 2018;31(1):47-60. 8. Gross O, Kashtan CE, Rheault MN, et al. Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome. Nephrol Dial Transplant. 2017;32(6):916-924. 9. Groopman E, Goldstein D, Gharavi A. Diagnostic utility of exome sequencing for kidney disease. Reply. N Engl J Med. 2019;380(21):2080-2081. 10. Arora P. Chronic kidney disease. Medscape. Updated August 1, 2019. Accessed September 16, 2020. https://emedicine.medscape.com/article/238798-overview.